Ferrer Internacional
Grupo Ferrer International is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States. In total, Ferrer's human health care products are commercialized in more than 95 countries, through 24 international affiliates (including joint ventures) and 70 partners and distributors. Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including the fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals. Its research centers in Spain and Germany, and manufacturing sites in Europe and Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors.
ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximize the chance of success in clinical development.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California.
Venter Pharma is a biotech company that aims to develop products in the field of gastroenterology to help patients and professionals. It arises on the bases of some research work carried out by PhD. Juan José Aragón Reyes and Alfonso Fernández Mayoralas in the Autonomous University of Madrid and Spanish National Research Council respectively. Venter Pharma focuses on the study of solutions for digestive pathologies, with especial attention to high population prevalence disorders such as lactose intolerance or inflammatory illnesses. Venter Pharma develops innovative products to make a clinical diagnosis easier, simpler and more effective. LacTEST®, is a new diagnosic drug for the diagnosis of lactose intolerance based on a new active substance: Gaxilose
Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic platform and turn them into advanced and personalized therapies. Oryzon Genomics has a growing portfolio, with two compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a potent and selective LSD1 inhibitor for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. The portfolio includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.